Role of cytoreductive surgery in recurrent ovarian cancer.
Cytoreductive surgery is well established in patients with primary ovarian cancer. The benefit of surgery in patients with recurrent ovarian cancer remains a controversial matter. There is a large heterogeneity in surgical results published in the literature, possibly caused by infrastructure, surgeons' philosophy and belief in adding various surgical skills. This might also be a result of different preoperative selection procedures. Further questions to be addressed are the definition of surgical end points and whether there are predictive factors for a successful surgery. The surgical end point in recurrent ovarian cancer should be complete resection. Predictive factors could help identify patients in whom complete resection is possible.
Harter
Philipp
P
Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig-Erhard-Str. 100, D-65199 Wiesbaden, Germany. p.harter@gmx.de
Hilpert
Felix
F
Mahner
Sven
S
Kommoss
Stefan
S
Heitz
Florian
F
du Bois
Andreas
A
D001291:Attitude of Health Personnel; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000601:surgery*; D010052:Ovariectomy / Q000379:methods*; D016896:Treatment Outcome